Mepsgen Co., Ltd.

MEPSGEN, a biotech company founded by Dr. YongTae Kim and Dr. Robert Langer in 2019, develops and commercializes human microphysiological systems (organ-on-a-chip) to recapitulate human organ-specific functions for better understanding the physiological and pathological mechanisms and for effectively screening drugs. With these studies supported by the technologies, the company has its own multiple new drug candidates, representative ones of which target Alzheimer's and brain tumors. The chip platforms are named MEPS-X and the new drug pipelines are named MG-X. A representative organ chip model is MEPS-BBB capable of mimicking the human blood-brain barrier with which drugs designed to target specific receptors at the BBB are evaluated in a mechanistic manner. A representative drug candidate is MG-PE3 currently in the preclinical stage, a bioinspired nanoparticle clearing amyloid with no adverse side effect or toxicity reportedly involved in antibody-based approaches.